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Malaria  remains  an important  health  threat  to  non-immune  travelers  with  the  explosive  growth  of  global
travel.  Populations  at high  risk  of  acquiring  malaria  infections  include  once  semi-immune  travelers  who
visit  friends  and  relatives,  military  forces,  business  travelers  and  international  tourists  with  destinations
to  sub-Saharan  Africa, where  malaria  transmission  intensity  is  high.  Most  malaria  cases  have  been  asso-
ciated  with  poor  compliance  with  existing  preventive  measures,  including  chemoprophylaxis.  High risk
groups  would  beneﬁt  immensely  from  an  efﬁcacious  vaccine  to protect  them  against  malaria  infection
and  together  make  up a sizable  market  for such  a vaccine.  The  attributes  of  an ideal  malaria  vaccine  for
non-immune  travelers  and  military  personnel  include  a  protective  efﬁcacy  of 80%  or  greater,  durability
for  at  least  6 months,  an  acceptable  safety  proﬁle  and  compatibility  with  existing  preventive  measures.
It  is  very  likely  that  a malaria  vaccine  designed  to effectively  prevent  infection  and  clinical  disease  in
the  non-immune  traveler  and  military  personnel  will  also  protect  semi-immune  residents  of  malaria-
endemic  areas  and  contribute  to  malaria  elimination  by reducing  or blocking  malaria  transmission.  The
RTS,S vaccine  (GlaxoSmithKline)  and  the  PfSPZ  Vaccine  (Sanaria  Inc) are  the  leading  products  that  would
make  excellent  vaccine  candidates  for these  vulnerable  populations.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license. Introduction
The cornerstone of malaria prevention has included prophylaxis
ith drugs, insecticide-treated bed nets and mosquito repellants;
owever, despite their high efﬁcacy, these interventions are only
artially successful in curtailing the disease’s global impact. The
orld Health Organization has set a strategic goal to license a vac-
ine by 2030 with protective efﬁcacy of at least 75% against clinical
alaria for at-risk groups in malaria-endemic areas [1,2]. In the past
0 years, many institutions across the world, including the United
tates (U.S.) Department of Defense (DoD), have made tremendous
rogress toward developing an effective human malaria vaccine for
t-risk populations worldwide and breakthroughs have been sig-
iﬁcant in recent years [3,4]. The exciting recent data on the top
wo vaccine candidates, RTS,S and PfSPZ Vaccine, suggest that an
ffective vaccine to protect certain target groups of semi-immune
nd non-immune individuals may  be licensed in the near future.
∗ Corresponding author at: Naval Medical Research Center, Malaria Depart-
ent, 503 Robert Grant Avenue, Silver Spring, MD 20910, United States.
el.: +1 301 295 0021; fax: +1 301 295 8025.
E-mail address: nimfa.c.tenezamora.mil@mail.mil (N. Teneza-Mora).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.004
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Global travel has accelerated the potential risk of being infected
with malaria parasites among non-immune travelers, underscor-
ing the importance of highly efﬁcacious preventive interventions.
In 2013 alone, over 1 billion international tourists traveled world-
wide [5], and extrapolating from data on U.S. travelers, 50% traveled
for leisure, 27% visited friends and relatives, 11% traveled as part of
their occupation and 5% for education purposes [6]. Sub-Saharan
Africa, which is considered to have a relatively high intensity of
malaria transmission, welcomed an estimated 36.2 million trav-
elers in 2013, representing a 5% increase from the previous year
[5,7]. In 2014, the total number of international tourists who  visited
sub-Saharan Africa increased by 3% despite the Ebola Virus Dis-
ease outbreak in West Africa [8]. Asia and the Paciﬁc region, where
rates of malaria transmission are relatively lower, experienced a
6% increase in international travelers, and received a total of 248
million visitors in 2013 [5]. In 2013, an estimated 36.5 million trav-
elers visited countries in Central and South America, where malaria
transmission intensity is low [5]. International tourist arrivals are
forecasted to steadily rise by 3.3% per year from 2010 to 2030, trans-
lating to an increase of approximately 43 million travelers per year
and reaching 1.8 billion by 2030 [5]. Data is scarce on estimates
of the number of children or elderly persons who travel inter-
nationally, but travel data for U.S. residents estimated that 7% of
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ravelers were children [9] and 9% were 65 years of age or older
10]. There is a critical need for effective protective measures with
he continuing growth of international travel to malaria endemic
egions [5]. In this article we will discuss non-immune populations
ho are at a particularly high risk of acquiring malaria infection
 these are international travelers and military personnel. Non-
mmune travelers are individuals who depart from countries which
re malaria-free or have low rates of malaria transmission and visit
r temporarily reside in regions with ongoing malaria transmis-
ion for leisure or work. These groups would greatly beneﬁt from a
accine to protect them against malaria infection.
. Non-immune travelers, deployed military and
nternational organization personnel at risk for acquiring
alaria
The risk of acquiring malaria is determined by multiple fac-
ors such as the location of the destination, season, transmission
ntensity, duration of travel, and use of personal protection. Spe-
iﬁc groups of travelers may  be at a higher risk of malaria parasite
xposure based on these factors. Nearly half of all global trips
re made by adventure tourists [11], who travel for an average
uration of 8 days but typically experience greater exposure to
he natural environment, resulting in higher risk of bites from
nfective mosquitoes. Business or occupational travelers to malaria
ndemic regions are generally well-informed but adherence to
hemoprophylaxis is often poor [12]. Travelers who volunteer for
nternational organizations or the Peace Corps are at increased risk
or acquiring malaria because they work in the ﬁeld and reside
n rural areas for 6 months or longer [13]. Foreign service per-
onnel and their family members who are stationed at diplomatic
osts in malarious regions are also at increased risk for acquiring
alaria [12,14]. Migrants who previously lived in malaria-endemic
egions or countries, have resided in non-malarious countries for
everal years and who then travel to their respective homelands
o visit friends and relatives (VFR travelers) are disproportionately
ffected by severe Plasmodium infections [15–18]. Persons who live
n areas with high intensity malaria transmission develop naturally
cquired immunity from repeated exposure to the parasite so that
n early adulthood, they develop a certain level of protection against
alaria and during an acute malaria infection may  have only mild
linical symptoms. However, this state of semi-immunity is par-
ial and wanes within months of living in malaria-free countries
r regions with very low malaria [18]. The VFR traveler remains at
isk for malaria infection though they tend to develop less severe
isease than the non-immune travelers [18]. Children born to once
emi-immune VFR travelers are particularly vulnerable to malaria
nfection because they have no innate protection and a low percent-
ge of this group accesses pre-travel consultation and/or complies
ith the health care providers’ personal protection recommenda-
ions. Another large segment of the population at increased risk
or malaria infection is the growing number of in-country travel-
rs who visit rural areas and reside in malaria-free capital cities and
egions, such as Nairobi, Kenya, the major cities of South Africa such
s Pretoria, Johannesburg, Cape Town, Durban, Sun City, Richards
ay, and highland areas in sub-Saharan Africa at 2000 meters ele-
ation above sea level or higher, where Plasmodium falciparum
pidemics are infrequent [19].
Military personnel from the international community deploy
orldwide to execute combat and security operations to promote
egional stability, engage in humanitarian missions and participate
n peacekeeping operations (Table 1). Throughout history, military
ersonnel have served in areas where they can potentially acquire
alaria, and outbreaks have signiﬁcantly impacted military oper-
tional capabilities and readiness.e 33 (2015) 7551–7558
The current anti-malaria strategies used by military include
chemoprophylaxis and personal protective measures to prevent
mosquito bites by wearing insecticide impregnated uniforms,
sleeping under bednets, and applying insect repellent. In addition,
mosquito control can be used in long-term and humanitarian oper-
ations, but may  not be possible in contingency operations [20–22].
3. Malaria in travelers
Many international travelers continue to acquire malaria while
visiting countries where the disease is endemic, and over 10,000
persons per year are reported to become ill with malaria after
returning from travel [23]. It is possible that malaria cases may  be
underreported because information is derived from systems which
rely on passive reporting [23]. Data collected from the EuroTravel-
Net sites from 2008 to 2012 showed an increase in the number of
imported malaria cases attributable to travel to sub-Saharan Africa
by persons who emigrated to malaria-free regions in Europe and
traveled back to their countries of origin to visit friends and rela-
tives, also known as VFR travelers [24]. A rising trend in the number
of imported malaria cases has been observed in the U.S. since 1973;
in 2012, 1683 cases of imported malaria were reported and nearly
80% were acquired from sub-Saharan Africa with a majority of the
cases coming from Nigeria, Sierra Leone, Ghana, and Liberia [15].
Among the imported malaria cases who reported the purpose of
travel, 54% were VFR travelers, 8.2% traveled as part of their occupa-
tion, 7.2% were involved in missionary work, 4.2% were students or
teachers, and 2.9% were tourists [15]. Chinese travelers represent
approximately 13% of worldwide travelers and China is actively
engaged as an industrial, manufacturing, and development part-
ner of numerous African countries [25]. Consequently, imported
malaria has become increasingly recognized in China, with 808
reported cases in the Zhejiang province from 2005 to 2014, and
at least 70% were acquired after travel to Africa primarily among
businessmen [26].
Despite the abundant availability of effective malaria pre-
ventive interventions such as chemoprophylactic medications,
insecticide-impregnated bed netting, and insect repellants, the
CDC’s National Malaria Surveillance System has continuously
received 5–10 reports of malaria-related deaths in the U.S. annually
[15,27,28]. A majority of the deaths have occurred among VFR trav-
elers who took suboptimal chemoprophylaxis regimens or did not
use malaria protective measures [28]. Additionally, travelers who
fall ill during travel may  ﬁnd it difﬁcult to access reliable medical
care, and those who develop malaria upon returning home may  be
treated by medical personnel unfamiliar with malaria, resulting in
delayed diagnosis.
4. Malaria among deployed military members
In the last century, malaria historically caused greater loss
of manpower than combat-related injuries during deployments
to tropical regions [29]. In 1972 the number of malaria cases
among U.S. military personnel sharply decreased from over 4000
per year [30] to less than 50 annually [31–33], but malaria
has remained a militarily relevant infectious disease negatively
impacting operational readiness among deployed forces. Deployed
forces to malaria-endemic regions have experienced outbreaks,
and noncompliance with personal protective measures had been
a recurrent risk factor associated with these outbreaks. During the
deployment of 30,000 U.S. military troops to Somalia from 1992 to
1993, P. falciparum malaria was diagnosed in 48 personnel whose
onset of illness occurred while still in-country; over 200 military
service members developed symptoms after their return to the U.S.
[34–36]. The risk factors for developing clinical malaria were failure
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Table  1
Examples of military personnel serving in areas with endemic malaria.
Time frame Military No. troops Place deployed Reason for deployment Number of reported
malaria cases
Reference
2001–10 US 2.1 million Iraq and Afghanistan Operation Iraqi Freedom and Operation
Enduring Freedom
∼450 [62,84]
2013 US 39,500 Afghanistan Training and mentoring Afghan units,
providing logistics and air support,
maintenance and intelligence units
11 [85,86]
2013 US 28,000 South Korea Standing watch on the demilitarized zone 3 [85,86]
2013 US 5500 Central and South
America
Working with allies and partners 1 [85,86]
2013 US 2500 Africa Maintain regional stability, respond to
crises and combat terrorism
6 [85,86]
2015 Special Operations
Command Africa
Not available Africa Promoting regional security, crisis
response, combating terrorism
Not available [87]
2014–5 US 2000 West Africa Build treatment facilities, establish
diagnostic testing centers, provide medical
training to contain Ebola outbreak
6 [88,89]
2013 British 9000 Afghanistan Security training to Afghan forces Not available [90]
2013 British Several
hundred
East and West Africa Logistics support to local civilian
community, conduct health care and
en
Not available [90]
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o comply with the prescribed chemoprophylaxis (deﬁned as miss-
ng any doses), failure to use bed nets all the time and not keeping
he uniform sleeves down [36]. Most of the malaria cases occurred
uring the ﬁrst ﬁve weeks of deployment, justifying the need for
apidly effective protection among troops who  deploy to these
egions [36]. The number of malaria cases among the troops quickly
aned by deployment week 10 after supervised chemoprophy-
axis with antimalarial medications and consistent reinforcement
f other personal protective measures were initiated.
The enormous impact of malaria threat on military operations
as demonstrated once again in 2003 during an outbreak among
25 U.S. Marines who deployed to Liberia to provide security ser-
ices for the U.S. Embassy [37]. The Marine unit spent only 10
ays in Liberia, and eighty Marines developed acute febrile illness
ithin one day of leaving the country. Forty-four members were
onﬁrmed to have malaria and eventually recovered, but 5 mem-
ers developed severe, complicated malaria, requiring critical care
nd prolonged hospitalization. All malaria cases fully recovered.
egative outcomes were largely associated with poor adherence
o chemoprophylaxis and personal protective measures [37].
Approximately 40,000 French military members are deployed
o various malaria-endemic African countries annually, and from
002 through 2006, over 1700 cases of P. falciparum malaria were
eported among French soldiers who were expected to take malaria
hemoprophylaxis [20]. In 2009, an outbreak of malaria cases was
eported among 14 out of 110 French military members who  were
eturning from Cote d’Ivoire after a four-month operational assign-
ent; the outbreak was associated with poor compliance with
hemoprophylaxis despite the provision of education on the pre-
entive measures on a regular basis [38].
A fatal case of P. falciparum malaria in a young U.S. Navy active
uty member who was deployed in Liberia in 2009 served as a
obering reminder of the severe consequences of non-adherence to
ersonal protective measures and the crucial role of careful plan-
ing, preparation and compliance with force health protection [39].
he enforcement of malaria protective measures by military com-
ands has likely resulted in a reduction of fatal malaria cases in
he U.S. military in the recent years. However, outbreaks of malaria
nfection among U.S. troops and other military forces will likelygineering community building projects
acekeeping operations Not available [91]
occur in the near future as long as they continue to deploy to malar-
ious regions [33,40–42].
5. Justiﬁcation for developing a malaria vaccine for
travelers and military
The occurrence of malaria-related morbidity and mortality
among travelers and military members will likely continue with the
growth of international travel and deployments to malaria endemic
regions. Current malaria chemoprophylaxis regimens have been
shown to be highly efﬁcacious in preventing infection among non-
immune individuals [43–46]. However, these measures are only as
good as the rate of compliance in which they are implemented. The
GeoSentinel Global Surveillance network has demonstrated that
40–44% of travelers who  presented at European and U.S. surveil-
lance sites with acute illness during or after returning from their
trip sought pre-travel advice from a health-care provider [47–49].
Among persons diagnosed with malaria who sought medical assis-
tance at various GeoSentinel Global Surveillance clinics worldwide,
only 27–37% reported pre-travel health consultation and 15% actu-
ally took malaria chemoprophylaxis [47,50]. Imported malaria was
diagnosed disproportionately among VFR travelers, but only 18%
reported pre-travel visits [47]. The VFR travelers’ perception of
low risk for severe malaria, coupled with their desire to con-
form with friends and relatives, who generally do not use personal
protective measures, contribute to their failure to seek pre-travel
health advice and use malaria preventive measures [51]. VFR trav-
elers who  use protective measures may  be viewed by their friends
and relatives as overreacting to a “normal illness”, highlighting
their difference from the local population [51]. Poor compliance
with malaria chemoprophylaxis among all travelers may  also be
attributed to unpleasant side effects associated with antimalarial
drugs [52]. These barriers to successful malaria prevention among
high risk groups call for extra effort to encourage the use of personal
protective measures, to include an efﬁcacious malaria vaccine.Despite readily available personal protective interventions,
poor compliance has contributed to outbreaks of malaria among
military populations. During a large malaria outbreak among
U.S. Marines who  were deployed to Somalia, only 56% of the
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Characteriscs of a Malaria Vaccine for Military and Travelers 
• US FDA Licensed* 
• Vacci ne eﬃca cy >80% 
• Cross-strain protecon 
• Time to protecon = 2 weeks aer last dose 
• Duraon of protecon > 6 months 
• Regimen = Two-do se plus booster 
* Required for vaccines administered to U.S. military and for 
use in the U.S. 554 N. Teneza-Mora et al. / V
ervice members reported compliance with the chemoprophylaxis
egimen [35]. During another outbreak of P. falciparum malaria
mong U.S. Army soldiers deployed in Sierra Leone, a mere 3%
eported using bed-nets and permethrin-treated uniforms and
nly 1% applied insect repellant [53]. The most common reasons
iven for noncompliance with taking antimalarial drugs were
astrointestinal side effects, forgetfulness, and low perception of
isk [54,55]. Medication noncompliance was also attributable to
he difﬁculty of keeping up with chemoprophylaxis medications
n the midst of multiple stressors during deployment operations
55,56]. A multi-step prevention procedure may  be challenging
o execute due to combat environment stress, and simplicity of
rocedure would enhance compliance. Additional challenges may
e precipitated by disruptions of supply chains that could result in
rug shortages and unavailability [54]. Multiple historical events
ave illustrated the vulnerability of deployed military members
n malaria-endemic regions and underscore the critical need for a
impliﬁed, practical approach for malaria force protection, which
ncludes the use of an efﬁcacious vaccine.
Military personnel from malaria endemic regions may  serve as
eservoirs of infection and contribute to the spread of drug resistant
trains and reintroduction into areas where malaria has been elimi-
ated [57]. Likewise, military serving in international peacekeeping
issions in malaria-endemic areas may  import malaria into other
ountries. This has been reported in a contingent of Guatemalan
oldiers and civilian support staff on a UN peacekeeping mission
n the Democratic Republic of Congo who imported chloroquine-
esistant P. falciparum malaria to Guatemala [58], one of the few
ocations where chloroquine is still a viable treatment for P. falcip-
rum malaria.
The addition of a highly efﬁcacious malaria vaccine can be
 practical way to combat the decreasing efﬁcacy of numerous
rst-line antimalarial drug therapies. Initially observed near the
hai-Cambodian border in the late 1980s, meﬂoquine resistance is
ow prevalent in parts of Southeast Asia and has been reported
n the Amazon region of South America, India and Africa [59]. The
etection of artemisinin resistance along the Thai-Cambodian bor-
er poses a global health threat to the efﬁcacy of Artemesinin
ombination Therapies or ACTs, which are currently the frontline
reatment for P. falciparum malaria worldwide [60,61]. Resistance
o CDC-recommended malaria chemoprophylactic medications,
tovaquone and meﬂoquine, was detected in 3% and 2% of the
lood samples tested at the CDC, respectively [15]. The exponential
rowth of global travel may  result in the spread of drug resistance
nd eventually render current therapeutic and preventive drugs
neffective.
. Requirements of a vaccine for the protection of
on-immune travelers and military members against
alaria
The ideal malaria vaccine for non-immune travelers and mili-
ary members should have the appropriate vaccine efﬁcacy for the
uration of travel or deployment while remaining safe and tolerable
Fig. 1). A malaria vaccine for the military must be developed with
perational requirements in mind. A minimum vaccine protective
fﬁcacy of 80% would maintain effective combat-related operations
nd reduce the impact of the disease on medical and logistics sup-
ort. Due to the genetic diversity of P. falciparum,  a vaccine must
ave the ability to provide cross-strain protection to be effective
orldwide. Troops may  receive less than a two week notice before
eparting for their operational assignment, therefore it is impor-
ant that protective immunity be achieved within two  weeks after
he last dose. The need for rapid achievement of the target vaccine
fﬁcacy is illustrated by the U.S. military experience with malariaFig. 1. Characteristics of a malaria vaccine for military and travelers.
outbreaks in Somalia and Liberia. The most severe malaria cases
occurred during the ﬁrst 5 weeks of U.S. service members’ arrival in
Somalia while the U.S. Marines who  acquired malaria in Monrovia
were on-site for only 10 days [36,37]. The ﬁrst dose(s) of the vaccine
could be administered soon after entry on active duty followed by a
boost prior to deployment to malaria endemic areas. The time and
logistics resources required for preparing military personnel for
deployment may  be limited; an initial immunization regimen upon
entry into the military followed by a single boost prior to deploy-
ment would be a practical schedule for the ideal malaria vaccine. A
vaccine which maintains protection for at least one year would be
highly useful among U.S. troops whose average deployment lasts
for 7.7 months [62]. However, many missions are of much shorter
duration–four to ﬁve months, such as humanitarian missions and
the recent deployments to West Africa in support of the Ebola
response–Operation United Assistance. A vaccine that is efﬁcacious
for at least 6 months would be of use in short-term deployments
and could balance the challenges associated with developing a vac-
cine with longer durability. Lastly, a tolerable vaccine product with
minimum side effects will likely enhance U.S. military members’
compliance with vaccination.
The ideal malaria vaccine must be compatible with other malaria
protective interventions and vaccines required by the military for
mitigating other infectious disease threats. The ﬁrst generation
vaccine would not necessarily replace the system of protective
measures currently practiced in the military but the overarching
goal is to develop a highly effective vaccine that can eventu-
ally supplant malaria chemoprophylaxis. Most importantly, the
malaria vaccine for U.S. military members must be licensed by
the Food and Drug Administration (FDA). FDA  licensure requires
compliance with manufacturing, documentation and performance
requirements ensuring that the product will perform as advertised.
The malaria vaccine being developed to protect military forces
may be applicable for preventing malaria in civilian non-immune
travelers. Most individuals who  travel for vacation prepare for their
trip 60–90 days prior to departure [6]. However, on average, busi-
ness travelers initiate their pre-travel preparation 30 days before
the onset of the trip [6]. An immunization schedule in which the
initial regimen is administered when travel is ﬁrst planned fol-
lowed by a boost prior to departure could be a feasible vaccine for
non-immune travelers. A vaccine that can induce a rapid immune
response, preferably within 14 days of completing the regimen,
would be desirable and should be considered by vaccine develo-
pers. Most travelers will be at their destinations for 7–10 days, but
VFR travelers stay longer (mean = 22 days), and those who travel
for humanitarian work stay even longer (mean = 3–4 months), so
the 6-month duration of protective efﬁcacy would be sufﬁcient
[11,16]. As in the military, non-immune travelers are more likely to
be compliant with a vaccine that has a tolerable side effect proﬁle.
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Table  2
Characteristics of the two  leading pre-erythrocytic malaria vaccines.
RTS,S-AS01 PfSPZ Vaccine
Sponsor GlaxoSmithKline (Belgium) Sanaria Inc. (USA)
Stage of Development Positive scientiﬁc opinion from European Medicines Agency
(EMA) [69]
Four-stage clinical development plan (CDP) being
implemented by Sanaria in coordination with the
International PfSPZ Vaccine Consortium [4]
Description Hybrid virus-like particle Live, aseptic, puriﬁed sporozoites from salivary glands of
mosquitoes, ﬁlled in vials and cryopreserved
Antigen Circumsporozoite protein Whole, radiation attenuated P. falciparum sporozoites (Strain
NF54)
Adjuvant AS01 None
Storage 2–8 ◦C Liquid nitrogen vapor phase
Route  of Immunization Intramuscular Direct venous inoculation
Current Vaccination Protocol
and Efﬁcacy (published data)
Phase 3: Phase 1 with CHMI:
3-dose primary = 50 g RTS,S at months 0, 1 and 2 [68] Five doses of 1.35 × 105 PfSPZ at 0, 1, 2, 3, and 5 months [83]
Efﬁcacy: Reduced clinical malaria cases in 5–17 month children
28% and 18% in 6–12 week infantsa,b [68]
Efﬁcacy: 100% (6/6) [83]
3-dose primary + 18-month booster [68]
Efﬁcacy: Reduced clinical malaria cases in 5–17 month children
36% and 26% in 6–12 week infantsa,b [68]
Regimens under Investigation
and Efﬁcacy
Phase 1 with CHMI: Phase 1 with CHMI:
Delayed Fractional Dose = Three doses at months 0, 1 (50 g RTS,S)
and 7 (10 g RTS,S) formulated in AS02 rather than AS01 [72]
Three doses of 4.5 × 105 or 9.0 × 105 PfSPZ at weeks 0, 8 and
16  [pending]
Efﬁcacy: Protected 86% (6/7) [72] Efﬁcacy: [pending]
Current Clinical Trials NCT01857869 (USA) NCT01988636 (Mali)
NCT02015091 (USA)
NCT02132299 (Tanzania)
NCT02215707 (USA)
NCT02418962 (Equatorial Guinea)
nths.
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b Children were followed for a median of 48 months and young infants for 38 mo
The WHO  established the Malaria Vaccine Technology Roadmap
trategic goal to license a malaria vaccine by 2030 which targets P.
alciparum and P. vivax with a 75% efﬁcacy for the prevention of clin-
cal malaria in at-risk groups in endemic areas [1]. Target groups for
his goal include populations living in areas with signiﬁcant malaria
ransmission as well as non-immune individuals migrating to or
emporarily visiting or working in malaria-endemic areas [2]. Other
HO  preferred product vaccine characteristics include efﬁcacy
asting at least two years with booster doses to be given no more
requently than once a year, compatibility with other childhood
accinations (as speciﬁed in the Expanded Program on Immuniza-
ion) and acceptable safety and tolerability [2]. It is very likely that a
alaria vaccine designed to effectively prevent infection and clini-
al disease in the non-immune traveler and military personnel will
lso protect semi-immune residents of malaria-endemic areas and
ontribute to malaria elimination by reducing or blocking malaria
ransmission.
. Malaria vaccines under development for non-immune
ravelers and U.S. military personnel
Vaccines are currently being developed against P. falciparum,
hich causes over 90% of fatal malaria cases. A vaccine that
rotects against P. vivax could help decrease morbidity in travelers
nd critical losses of manpower in deployed military operational
nits suffering from acute illnesses or relapses of infection and
hould be a high priority for malaria vaccine developers. Ideally,a single malaria vaccine would protect against both P. falciparum
and P. vivax.
Partially immune individuals who are infected with the malaria
parasites may  have mild symptoms, but non-immune persons with
acute malaria can have severe clinical manifestations that may
lead to death or permanent sequelae. Hence, a vaccine for non-
immune persons should provide sterile immunity. Vaccines that
target the pre-erythrocytic stage would be the most suitable for the
non-immune traveler because they could prevent parasitic infec-
tion and clinical disease. Pre-erythrocytic vaccines target the
sporozoites or liver stage parasites, and they primarily stimulate
the formation of neutralizing antibodies to the sporozoites’ surface
coat proteins and/or cell-mediated immunity to interfere with the
maturation of liver stage parasites into blood stage parasites, and
therefore prevent infection and clinical disease. The WHO  plans
to accomplish the Malaria Vaccine Technology Roadmap strategic
objectives through the clinical development of vaccines that can
prevent parasitemia, and therefore, clinical malaria, and vaccines
to interrupt malaria transmission (VIMT) in the endemic areas.
VIMT encompass pre-erythrocytic vaccines that can induce sterile
immunity and reduce or block transmission by preventing human
infection.
The two pre-erythrocytic vaccines that have shown the highest
levels of protection in clinical trials are the RTS,S vaccine (Glaxo-
SmithKline; GSK) and the PfSPZ Vaccine (Sanaria Inc) (Table 2). The
RTS,S vaccine is the ﬁrst malaria vaccine to be advanced to Phase
3 clinical trials. It is a recombinant subunit vaccine that consists
of the circumsporozoite protein (CSP) fused to hepatitis B surface
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ntigen (HBsAg), and the hybrid has been shown to induce bet-
er immunogenicity when combined with potent adjuvants. Early
fforts in the research and development of the RTS,S malaria vac-
ine from preclinical studies through multiple phase 1, 2 and 3
linical studies have been reviewed elsewhere [63–66]. Vaccine
fﬁcacy against clinical malaria 18 months following vaccination
f infants and young children was 27% and 46%, respectively, and
aned over time in both age categories [67,68] (Table 2). The Euro-
ean Medicines Agency adopted a positive scientiﬁc opinion for
TS,S in July 2015 [69]; GSK indicated that RTS,S is intended “exclu-
ively for use outside the EU” to “protect children in Africa from
alaria” [70].
The Walter Reed Army Institute of Research (WRAIR) in collabo-
ation with GSK and PATH Malaria Vaccine Initiative (MVI) have an
ngoing clinical trial to evaluate the safety, efﬁcacy, and immuno-
enicity of RTS,S with the delayed fractional dose regimen [71] that
as shown to give 86% sterile protection against controlled human
alaria infection (CHMI) in an early phase 1 trial [72]. Most phase
, 2 and 3 clinical trials with RTS,S after the 1997 study were con-
ucted using a regimen of the standard 0.5 mL  dose of RTS,S given
t 0, 1 and 2 months. In the delayed fractional dose regimen, RTS,S
s administered at standard doses at 0 and 1 month and 1/5th the
tandard dose at 7 months [71].
Gene-based vaccine approaches with heterologous prime-boost
ave been developed to induce strong cellular immune responses
gainst the liver-stage of P. falciparum.  The protective efﬁcacy of
ene-based vaccines encoding one or more Pf antigens has been
ow to modest, ranging from 21% with chimpanzee adenovirus
3 (ChAd63)-Modiﬁed Vaccinia Ankara (MVA) encoding multi-
le epitope–thrombospondin-related adhesion protein (ME-TRAP)
n a prime-boost regimen [73–75] to 27% with DNA-adenovirus
erotype 5 encoding circumsporozoite protein (CSP) and apical
embrane antigen 1 (AMA1) in a prime-boost regimen [76]. In a
ecent phase 1 clinical trial, ChAd63 prime/MVA boost vaccine plat-
orm encoding for ME-TRAP administered with the RTS,S standard
 dose vaccine series demonstrated a short-term protective efﬁ-
acy of 82% [77,78]. The combination of the ChAd63 ME-TRAP
rime/MVA ME-TRAP boost with the RTS,S delayed fractional dose
egimen is currently being evaluated in a clinical trial [79].
The Sanaria® PfSPZ Vaccine is the ﬁrst malaria vaccine to provide
00% protective efﬁcacy against CHMI. It applies the whole organ-
sm vaccine approach that has been successfully utilized in the
evelopment of licensed vaccines against other infectious diseases
nd is based on the studies done in the 1970s–1990s, which demon-
trated greater than 90% protection lasting for at least 10 months
n human subjects immunized by the bite of mosquitoes contain-
ng radiation attenuated sporozoites [80–82]. The PfSPZ Vaccine
onsists of aseptic, puriﬁed, cryopreserved, radiation-attenuated
. falciparum sporozoites. The vaccine protected six of six malaria
aïve subjects who received the highest cumulative dose of the vac-
ine (ﬁve doses of 1.35 × 105 PfSPZ) [83]. Currently, multiple clinical
rials are being conducted by Sanaria, Inc., in collaboration with
he U.S. Military Malaria Vaccine Program (USMMVP), and other
artners in the U.S. and abroad, to expand the clinical experience
nd obtain valuable data on durability of protection, protection
gainst heterologous strains of P. falciparum,  optimum regimen, and
fﬁcacy in semi-immune subjects to support the licensure of this
accine.
. ConclusionGlobal travel and changing military missions increase the poten-
ial risk of malaria infection among non-immune international
ravelers and military personnel, two groups which constitute
 substantial market for a malaria vaccine. Personal protectivee 33 (2015) 7551–7558
measures, including chemoprophylactic medications, which have
been proven to be effective, have not successfully prevented
malaria-related morbidity and mortality in this population due
to noncompliance and other related factors. A vaccine protective
efﬁcacy of at least 80% and preferably greater than 90%, dura-
bility for at least 6 months, acceptable tolerability/safety proﬁle,
and compatibility with current malaria protective measures would
be desirable characteristics of a vaccine to protect non-immune
travelers and military personnel. The uptake of a licensed malaria
vaccine among high risk populations who do not seek pre-travel
consultation may  be greatly enhanced by providing culturally sen-
sitive traveler health education through printed and broadcast
media. Phase 1 clinical studies have shown that a vaccine protec-
tive efﬁcacy of at least 80% against CHMI was achievable with the
RTS,S vaccine with delayed fractional dose and the PfSPZ Vaccine.
Clinical studies are being conducted on both vaccine candidates to
obtain valuable data on the optimum regimen that affords protec-
tion against heterologous strains of P. falciparum,  and greater than 6
months durability of protection to support licensure of an effective
vaccine for travelers and military members.
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